REFERENCES
- Holt RIG. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology 2008; 22(Suppl.): 28–37.
- Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry 2007; 190: 129–134.
- Tworoger SS, Eliassen H, Sluss P, Hankinson S. A prospective study of plasma prolactin concentrations and risk of premenopausal and post menopausal breast cancer Journal of Clinical Oncology 2007; 25: 1482–1488.
- Harvey PW, Everett DJ, Springall CJ. Adverse effect of prolactin in rodents and humans: breast and prostate cancer. Journal of Psychopharmacology 2007; 22(Suppl.): 20–27.
- Molitch ME. Medication-induced hyperprolactinaemia. Mayo Clinic Proceedings 2005; 80: 1050–1057.
- Byerly M, Suppes T, Tran Q, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinaemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. Journal of Clinical psychopharmacology 2007; 27: 639–661.
- Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinaemia. Pharmacotherapy 2008; 29: 64–73.
- Wang PS, Walker AM, Tsuang MT. Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry 2002; 59: 1147–1154.
- Dalton SO, Mellemkajer L, Thomassen L, Moertensen PB, Johansen C. Risk of cancer in a cohort of patients hospitalised for schizophrenia in Denmark. Schizophrenia Research 2005; 75: 315–324.
- Haddad PM, Weick A. Antipsychotic induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291–2314.
- Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 2008; 22(Suppl.): 46–55.
- Markianos M, Hatzimonalis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, Olanzapine, risperidone, sulpiride, or haloperidol. European Archives of Psychiatry Clinical Neuroscience 2001; 251: 141–146.
- Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. American Journal of Psychiatry 2005; 162: 1010–1012.
- Serri O, Chik CL, Ur E, Ezatt S. Diagnosis and management of hyperprolactinaemia. Canadian Medical Association Journal 2003; 169: 575–581.
- Peveler RC, Branford D, Citrome L . Antipsychotics and hyperprolactinaemia: Clinical recommendations. Journal of Psychopharmacology 2008; 22(Suppl.):98–103.
- Wesselman U, Windgassen K. Galactorrhea: subjective response by schizophrenia patients. Acta Psychiatrica Scandinavia 1995; 91: 152–155.
- Bun-Hee L, Yong-Ku K. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006; 30: 658–662.
- Judd F, Armstrong S, Kulkarni J. Gender-sensitive mental health care. Australasian Psychiatry 2009; 17: 105–111.